Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 15;41(11-12):1222–1239. doi: 10.1177/03331024211018137

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© International Headache Society 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — Subgroup-analysis of mABs, TPM and BoNTA for the prevention of episodic and chronic migraine. X-axis is depicted as standard decimal plot. Box size indicates weighting. All available antibodies showed overall superiority regarding the 50% response rate compared to placebo. The overall effect size of TPM for the prevention of migraine compared to placebo was the highest in our analysis. Robust data exist for TPM in the prevention of episodic migraine. When weighting studies according to episodic and chronic migraine the combined effect size was not significantly superior compared to placebo. This effect is caused by the abundance of large, randomized controlled studies evaluating TPM for chronic migraine and thus yielding a broad CI. Corresponding to international and national recommendations, BoNTA showed superiority in the prevention of chronic migraine regarding 50% response rate. Data to support its use in the prevention of episodic migraine is scarce and not consistent. The combined effect size of all studies when weighting regarding episodic or chronic migraine still results in a favourable outcome for BoNTA of an OR of 1.36 (CI: 1.00–1.86).